

**CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED**  
(Company Registration No. 200505118M)  
(the “**Company**”)

---

**COMPLETION OF THE PROPOSED CORPORATE EXERCISES**

---

The Board of Directors (the “**Board**” of the “**Directors**”) of China Medical (International) Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) refers to the Company’s announcements on 26 August 2018, 17 December 2018 and 31 December 2018, and the circular despatched to shareholders of the Company on 7 December 2018 in relation to, *inter alia*, the Proposed Corporate Exercises (the “**Previous Announcements**”).

Unless otherwise defined, all capitalised terms used in this Announcement shall bear the same meanings as defined in the Previous Announcements.

The Board is pleased to announce that the Company had on 10 January 2019 completed:

- (a) the Proposed Share Consolidation, following the share consolidation of every two (2) ordinary shares in the capital of the Company held by shareholders of the Company at the Books Closure Date into one (1) Consolidated Share;
- (b) the Proposed Deferred Liability Conversion, following the allotment and issuance of an aggregate of 3,214,285,714 Conversion Shares at a conversion price of S\$0.0011 to the Deferred Liability Assignees;
- (c) the Proposed Share Subscription, following the allotment and issuance of 2,857,142,857 Subscription Shares at an issue price of S\$0.0014, and 952,380,952 free Investment Warrants, each convertible into one Consolidated Share at an exercise price of S\$0.0014, to the Anchor Investor; and
- (a) the Proposed Introducer Shares Issue, following the allotment and issuance of 142,857,143 Introducer Shares at an issue price of S\$0.0014 to the Introducer.

The Conversion Shares, Subscription Shares and Introducer Shares are issued free from all claims, charges, liens and other encumbrances and shall rank *pari passu* in all respects with the existing Consolidated Shares, save that they shall not rank for any entitlements, distributions, dividends or rights (if any), the record date of which falls on or before the date of issue of the Conversion Shares, Subscription Shares and Introducer Shares.

The total number of Shares of the Company has increased from 4,406,389,409 Shares post-completion of the Proposed Share Consolidation to 10,620,675,123 Shares, following the completion of the Proposed Deferred Liability Conversion, Proposed Share Subscription and Proposed Introducer Shares Issue.

**BY ORDER OF THE BOARD**  
**Hano Maeloa**  
**10 January 2019**

---

*This Announcement has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”) for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalyst. The Sponsor has not verified the contents of this Announcement.*

*This Announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this Announcement, including the accuracy,*

*completeness or correctness of any of the information, statements or opinions made or reports contained in this Announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg)).*